Crestor: What People Actually Pay for Rosuvastatin

Generic Rosuvastatin Changed the Price Picture Entirely

When AstraZeneca's patent on Crestor expired in 2016, generic rosuvastatin entered the market and prices dropped by roughly 95%. A 30-day supply of rosuvastatin 10 mg or 20 mg now costs between $4 and $18 at most retail pharmacies when patients use a discount card or pay cash. This price collapse turned one of the most expensive branded statins into one of the cheapest cholesterol medications available.

The FDA approved the first generic rosuvastatin calcium tablets in April 2016, and multiple manufacturers now compete for market share (FDA Orange Book). Competition among generic producers (including Hikma, Aurobindo, Teva, and others) has kept prices low. Pharmacy benefit managers place generic rosuvastatin on Tier 1, which means the lowest possible copay for insured patients. At Costco, 90 tablets of rosuvastatin 20 mg can cost under $10 without any insurance at all. Mark Cuban's Cost Plus Drugs pharmacy lists rosuvastatin 20 mg at $4.20 for a 90-day supply, representing one of the lowest prices on the market for any statin.

Patients who still receive brand-name Crestor face a different reality. Without manufacturer coupons, a 30-day supply of brand Crestor runs $280 to $370. Some patients on Reddit forums report being dispensed brand accidentally or by formulary restriction and receiving bills exceeding $250 for a single month.

What Insured Patients Report Paying

The majority of insured patients in the United States pay between $0 and $15 per month for generic rosuvastatin. Tier 1 generic copays at most commercial health plans fall in this range, and many high-deductible health plans still cover preventive statins with no cost-sharing under ACA preventive care mandates.

A 2022 analysis in the American Journal of Preventive Medicine found that statin adherence improved by 4 to 6 percentage points when copays were eliminated under value-based insurance design programs (PubMed). This finding is consistent with what patients describe online. On r/HealthInsurance and r/personalfinance, multiple users report $0 copays for rosuvastatin after their plans classified it as preventive. One user wrote: "My doctor prescribed rosuvastatin 10 mg, and I literally pay nothing. My insurance covers it 100% as preventive."

Medicare Part D beneficiaries also benefit from low generic pricing. The Centers for Medicare & Medicaid Services lists rosuvastatin among the drugs covered under the $2 generic copay provisions of the Inflation Reduction Act for qualifying low-income subsidy enrollees (CMS.gov). Even without LIS, standard Part D plans place rosuvastatin at Tier 1 with copays typically between $1 and $11.

Not every patient gets these prices. Patients with certain Medicare Advantage plans or narrow formularies may still face $20 to $40 copays if their plan prefers atorvastatin over rosuvastatin. Switching between statins based purely on formulary cost is common and well-documented in pharmacy benefit management literature.

What Uninsured and Cash-Pay Patients Report

Uninsured patients have more options for affordable rosuvastatin than for almost any other prescription medication. The drug appears on multiple $4 generic lists (Walmart, Kroger, Publix), and GoodRx coupons routinely bring the price to $8 to $18 for a 30-day supply at CVS, Walgreens, and Rite Aid.

On Reddit's r/uninsured and r/povertyfinance, patients describe rosuvastatin as one of the few prescriptions they can afford without coverage. A frequently cited strategy involves using the Costco pharmacy (which does not require a membership for prescription pickups) to obtain 90-day supplies for under $12. Another common suggestion is Cost Plus Drugs, where the transparent markup model yields a price of $4.20 for a 90-day supply of rosuvastatin 20 mg.

Patients who order through mail-order pharmacies such as Amazon Pharmacy report prices of $6 to $14 per month with free delivery for Prime members. One user on r/pharmacy stated: "I switched my mom to Amazon Pharmacy and her rosuvastatin went from $22 to $6 per month with no insurance."

The contrast between these real-world prices and the nominal Average Wholesale Price (AWP) is striking. AWP for generic rosuvastatin 20 mg is listed at approximately $45 to $70 for 30 tablets in pharmacy databases, but almost no patient pays AWP. The difference reflects the heavy discounting that generic competition and pharmacy benefit managers produce in the statin market.

Brand-Name Crestor: Who Still Pays Premium Prices

Despite widespread generic availability, a small subset of patients still fills brand-name Crestor prescriptions. AstraZeneca reported residual U.S. Crestor revenue of approximately $200 million in 2023, indicating that tens of thousands of prescriptions for brand Crestor are still dispensed annually.

Three groups account for most brand-name fills. First, patients whose physicians write "dispense as written" (DAW) on the prescription, sometimes at the patient's request based on perceived quality differences. Second, patients receiving manufacturer copay cards that reduce brand costs to $0 to $10 per month, making brand and generic economically equivalent for the patient while the insurer absorbs the difference. Third, patients in U.S. territories or specific plan designs where generic substitution laws differ from mainland rules.

The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced the composite endpoint of major cardiovascular events by 44% in patients with normal LDL cholesterol but elevated high-sensitivity C-reactive protein (hsCRP above 2.0 mg/L), with a number needed to treat of 25 over 1.9 years of median follow-up (Ridker et al., NEJM 2008). This trial established rosuvastatin's evidence base for primary prevention. The clinical benefit is identical regardless of whether the patient takes brand or generic, as FDA bioequivalence standards require that generic rosuvastatin deliver the same plasma drug concentrations as brand Crestor (FDA bioequivalence guidance).

How Rosuvastatin Costs Compare to Other Statins

Rosuvastatin is priced similarly to atorvastatin (generic Lipitor) in the cash-pay market. Both drugs cost $4 to $18 per month at most pharmacies. Simvastatin (generic Zocor) and pravastatin (generic Pravachol) are comparably cheap. The meaningful price differences among statins have largely disappeared at the generic level.

The cost equivalence matters because prescribers sometimes default to atorvastatin due to older generic availability (it went generic in 2011, five years before rosuvastatin). A 2021 JAMA Network Open study found that atorvastatin accounted for 48% of all statin prescriptions in the U.S. versus 22% for rosuvastatin, a gap partly attributable to prescribing inertia rather than clinical superiority (PubMed). From a pure cost standpoint, patients and providers can choose between these two high-intensity statins without financial penalty.

Where cost does diverge is in the brand-name tier. Brand Lipitor is no longer actively marketed and is rarely dispensed, while brand Crestor still has limited distribution. Patients occasionally encounter pharmacies that stock only brand Crestor and must special-order the generic, which can cause delays. Calling ahead to confirm generic availability is a simple fix.

Patient-Reported Satisfaction With Rosuvastatin Value

Across Drugs.com user reviews (over 900 ratings for rosuvastatin), the drug receives an average score of 6.2 out of 10 for overall satisfaction. Cost is rarely cited as a negative factor for the generic. The most common complaints center on muscle pain (reported by approximately 15 to 20% of reviewers) and fatigue. Patients who tolerate the drug well frequently describe it as "cheap and effective" or rate it highly specifically because of affordability.

A pattern visible across Reddit threads in r/cholesterol and r/AskDocs shows that patients often arrive anxious about statin costs based on outdated brand pricing. They express relief upon learning that generic rosuvastatin is among the least expensive chronic medications available. One representative post from r/cholesterol reads: "Doctor put me on rosuvastatin 10 mg and I was bracing for a big pharmacy bill. Walked out paying $4. My LDL dropped from 168 to 82 in three months."

Selection bias is real in these forums. Patients who encounter billing problems or insurance denials are more likely to post about their experience than those who fill prescriptions without incident. The majority of the approximately 30 million statin users in the United States fill their prescriptions routinely without engaging in online discussions about cost (CDC NCHS data). Forum posts overrepresent both the most satisfied and most frustrated patients.

Strategies to Minimize Out-of-Pocket Costs

Five specific approaches consistently lower rosuvastatin costs for patients. First, requesting the generic by name on the prescription to prevent accidental brand dispensing. Second, using GoodRx, RxSaver, or similar discount platforms to compare pharmacy prices, since prices for the same generic can vary by $10 to $15 between pharmacies in the same zip code. Third, asking about 90-day fills, which typically cost less per tablet than 30-day fills and reduce pharmacy visits.

Fourth, checking whether the patient's health plan covers rosuvastatin at $0 under preventive care. The U.S. Preventive Services Task Force (USPSTF) recommends statin therapy for adults aged 40 to 75 with at least one cardiovascular risk factor and a 10-year ASCVD risk of 10% or greater (USPSTF recommendation). Under ACA Section 2713, health plans must cover USPSTF A- and B-rated recommendations with no cost-sharing. Rosuvastatin fills that qualify under this provision should cost $0, though patients may need to call their insurer or have their pharmacist submit the correct preventive billing code.

Fifth, for patients without any coverage, Cost Plus Drugs and Costco pharmacy consistently offer the lowest per-tablet prices nationwide. A 90-day supply of rosuvastatin 20 mg at Cost Plus Drugs runs $4.20 plus shipping, making annual medication costs under $25.

When Higher Doses Affect Price

Rosuvastatin is available in 5 mg, 10 mg, 20 mg, and 40 mg tablets. In the generic market, all four strengths are priced similarly, typically within $1 to $3 of each other for a 30-day supply. This pricing parity means that pill-splitting (using a higher-strength tablet and cutting it in half) offers minimal savings for rosuvastatin, unlike some other medications where the higher dose costs the same as the lower dose.

The 40 mg dose, which is the maximum approved dose, may face minor formulary restrictions. Some insurance plans require prior authorization for rosuvastatin 40 mg, preferring that patients first try 20 mg. The 2018 AHA/ACC cholesterol guideline recommends high-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) for patients with clinical ASCVD or LDL above 190 mg/dL (Grundy et al., Circulation 2019). When prior authorization is required, the prescriber typically submits the patient's LDL values and risk category. Approval rates are high.

Patients on the 5 mg dose, often used for those of Asian descent due to pharmacogenomic differences in ABCG2 transporter function, should verify pricing separately. Some pharmacies price the 5 mg tablet slightly higher than the 10 mg because of lower dispensing volume, though the difference is rarely more than $2 to $4 per month.

The Real Cost of Not Taking Rosuvastatin

Financial discussions about rosuvastatin are incomplete without context on the cost of untreated hyperlipidemia. The average cost of a first-time myocardial infarction hospitalization in the United States exceeds $25 to 000 in direct medical costs, according to AHA analysis (Virani et al., Circulation 2021). Statin therapy reduces ASCVD events by 25 to 35% per 1 mmol/L (39 mg/dL) reduction in LDL cholesterol, according to the Cholesterol Treatment Trialists' (CTT) meta-analysis of 170,000 participants across 26 trials (Baigent et al., Lancet 2010).

At $4 to $15 per month, rosuvastatin ranks among the most cost-effective preventive interventions in all of medicine. A cost-effectiveness analysis published in Annals of Internal Medicine estimated the incremental cost-effectiveness ratio (ICER) for statin therapy in primary prevention at approximately $3,500 per quality-adjusted life year (QALY) gained for moderate-risk patients, well below the $50,000 to $100,000 per QALY threshold commonly used in U.S. health policy (Pandya et al., Annals of Internal Medicine 2015).

The JUPITER trial demonstrated that even in patients with LDL cholesterol below 130 mg/dL, rosuvastatin 20 mg reduced cardiovascular events by 44% (HR 0.56; 95% CI 0.46 to 0.69; P<0.00001) over a median follow-up of 1.9 years, with a number needed to treat of 25 (Ridker et al., NEJM 2008). For a drug that costs less per month than a single cup of coffee at most cafes, the risk-benefit calculus is straightforward for eligible patients.